WO2006033713A3 - Methods for ciprofloxacin inhalation - Google Patents

Methods for ciprofloxacin inhalation Download PDF

Info

Publication number
WO2006033713A3
WO2006033713A3 PCT/US2005/028102 US2005028102W WO2006033713A3 WO 2006033713 A3 WO2006033713 A3 WO 2006033713A3 US 2005028102 W US2005028102 W US 2005028102W WO 2006033713 A3 WO2006033713 A3 WO 2006033713A3
Authority
WO
WIPO (PCT)
Prior art keywords
ciprofloxacin
inhalation
methods
relates
present
Prior art date
Application number
PCT/US2005/028102
Other languages
French (fr)
Other versions
WO2006033713A2 (en
Inventor
Johnny Lai
Allan Wagman
Pete Challoner
Ribhi Shawar
Andy Towell
Rahul Tak
Kay Huh
Original Assignee
Chiron Corp
Johnny Lai
Allan Wagman
Pete Challoner
Ribhi Shawar
Andy Towell
Rahul Tak
Kay Huh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Johnny Lai, Allan Wagman, Pete Challoner, Ribhi Shawar, Andy Towell, Rahul Tak, Kay Huh filed Critical Chiron Corp
Publication of WO2006033713A2 publication Critical patent/WO2006033713A2/en
Publication of WO2006033713A3 publication Critical patent/WO2006033713A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to dry power inhaled formulations containing ciprofloxacin for increased efficacy and decreased toxicity in treating microbial infections.
PCT/US2005/028102 2004-08-09 2005-08-09 Methods for ciprofloxacin inhalation WO2006033713A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60021004P 2004-08-09 2004-08-09
US60/600,210 2004-08-09

Publications (2)

Publication Number Publication Date
WO2006033713A2 WO2006033713A2 (en) 2006-03-30
WO2006033713A3 true WO2006033713A3 (en) 2006-08-24

Family

ID=36090429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028102 WO2006033713A2 (en) 2004-08-09 2005-08-09 Methods for ciprofloxacin inhalation

Country Status (1)

Country Link
WO (1) WO2006033713A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
BRPI0913021A2 (en) * 2008-05-15 2015-10-13 Novartis Ag pulmonary distribution of a fluoroquinolone
SI2346509T1 (en) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalation of levofloxacin for reducing lung inflammation
HUE038428T2 (en) 2008-10-07 2018-10-29 Horizon Orphan Llc Aerosol fluoroquinolone formulations for improved pharmacokinetics
BR112012004692B8 (en) 2009-09-04 2021-05-25 Mpex Pharmaceuticals Inc solution comprising levofloxacin for use in a method of treating cystic fibrosis in a human.
WO2018071427A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
CN114886861A (en) * 2022-06-30 2022-08-12 苏州大学 Ciprofloxacin hydrochloride composition particles for pulmonary delivery and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284776A (en) * 1993-08-17 1994-02-08 Abbott Laboratories Aqueous quinolone concentration assay
US20030186894A1 (en) * 1999-10-29 2003-10-02 Kuo Mei-Chang Dry powder compositions having improved dispersivity
US20040254194A1 (en) * 2003-02-10 2004-12-16 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284776A (en) * 1993-08-17 1994-02-08 Abbott Laboratories Aqueous quinolone concentration assay
US20030186894A1 (en) * 1999-10-29 2003-10-02 Kuo Mei-Chang Dry powder compositions having improved dispersivity
US20040254194A1 (en) * 2003-02-10 2004-12-16 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs

Also Published As

Publication number Publication date
WO2006033713A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2006033713A3 (en) Methods for ciprofloxacin inhalation
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2007011962A3 (en) Treatment of cancer
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
TW200630367A (en) Substituted adenines and the uses thereof
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
EP1868628A4 (en) Compounds, compositions and methods for the treatment of poxvirus infections
WO2007017267A3 (en) Novel compounds
WO2010003533A3 (en) Pyridopyrimidine compounds as anti-tubercular agents
WO2007074406A3 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
PL2465493T3 (en) Topical compositions for the prevention and treatment of irritation of mucous cells
WO2007059226A3 (en) Photoactivatable antimicrobial agents
ZA200701629B (en) Gyrase inhibitors and uses thereof
EP1663959A4 (en) Novel amidine compounds for treating microbial infections
WO2006081182A3 (en) Antibacterial agents
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007124382A3 (en) Inhaled imipenem
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2006081178A3 (en) Antibacterial agents
MX2010005012A (en) Compositions for the treatment and prevention of eyelid swelling.
WO2008132021A3 (en) Fungicide mixtures
WO2007009701A3 (en) Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2006050826A3 (en) Treatment of mastitis with enrofloxacin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase